To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). The stem cell source was allogeneic related bone marrow (BM) (n = 53), allogeneic unrelated BM (n = 5), allogeneic unrelated peripheral blood (PBSC) (n = 2), syngeneic BM (n = 2), autologous BM purged (n = 9) or unpurged (n = 9), autologous PBSC (n = 10). Fifty-six patients (62%) were in first CR, 26 (29%) were Ͼ first CR, and eight (9%) were transplanted in relapse. Principal toxicities in both groups were mucositis and hepatotoxicity. Forty-five mg/kg etoposide resulted in greater hepatic toxicity (P = 0.03), and a higher incidence of VOD (23 vs 12%, P = 0.04) and acute GVHD grade III/IV (13 vs 5%, NS). The treatment-related mortality was 17% in the 30 mg/kg group and 33% in the 45 mg/kg group, mainly due to infections, intestinal pneumonia and GVHD. Hematological recovery of leukocytes 1/nl was comparable in both groups (17 vs 16 days). After a median follow-up of 16 months 19% in the 30 mg/kg group and 23% in the 45 mg/kg group relapsed. In patients who had undergone allogeneic related bone marrow transplantation in first CR no relapses occurred after a median follow-up of 3 years. For all patients the 3-year estimated disease-free survival was 62% in the 30 mg/kg group and 40% in the 45 mg/kg group (P = 0.03). For patients in first CR who underwent allogeneic related stem cell transplantation the 3 year disease-free survivals were 80% and 66%, respectively (P = 0.4). We conclude that etoposide 30 mg/kg or 45 mg/kg in combination with busulfan/cyclophosphamide is a highly active regimen 1-3 The use of allogeneic or autologous bone marrow transplantation increases the rate of long-term survival, although a substantial number of patients still relapse. 4, 5 The relapse rate after autologous transplantation in first CR is about 50% and after allogeneic transplantation about 20%. 6 It is possible that improved preparative regimens will reduce these relapse rates. The most common preparative regimens in acute myeloid leukemia are busulfan and cyclophosphamide or TBI plus cyclophosphamide. 7, 8 It has already been shown that an intensified preparative regimen can lower the relapse rate in allogeneic as well as in autologous transplantation. 5, 9, 10 We incorporated etoposide 45 or 30 mg/kg to a conditioning regimen consisting of busulfan (16 mg/kg) plus cyclophosphamide (120 mg/kg) to investigate the efficacy and toxicity of this new preparative regimen in patients with acute myeloid leukemia undergoing autologous or allogeneic stem cell transplantation. This combination was choosen based on the hypothesis that etoposide might have an additional antileukemic effect.
Intensive chemotherapy for acute myeloid leukemia results in 65-80% complete remissions, but only 20-30% of patients maintain a durable remission with standard consolidation therapies. [1] [2] [3] The use of allogeneic or autologous bone marrow transplantation increases the rate of long-term survival, although a substantial number of patients still relapse. 4, 5 The relapse rate after autologous transplantation in first CR is about 50% and after allogeneic transplantation about 20%. 6 It is possible that improved preparative regimens will reduce these relapse rates. The most common preparative regimens in acute myeloid leukemia are busulfan and cyclophosphamide or TBI plus cyclophosphamide. 7, 8 It has already been shown that an intensified preparative regimen can lower the relapse rate in allogeneic as well as in autologous transplantation. 5, 9, 10 We incorporated etoposide 45 or 30 mg/kg to a conditioning regimen consisting of busulfan (16 mg/kg) plus cyclophosphamide (120 mg/kg) to investigate the efficacy and toxicity of this new preparative regimen in patients with acute myeloid leukemia undergoing autologous or allogeneic stem cell transplantation. This combination was choosen based on the hypothesis that etoposide might have an additional antileukemic effect. [11] [12] [13] It shows high antineoplastic activity against a wide range of malignancies and a steep dose response with low extramedullary toxicity at standard dose.
14 Etoposide has been administered in doses up to 60 mg/kg, which represents a 10-fold increase over the conventional dosage. The dose-limiting factor of highdose etoposide is stomatitis. Other side-effects are hepatic and pulmonary toxicity, especially in extensively pretreated patients. 
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Patients and methods
Between 1991 and 1998, 90 patients were enrolled in the protocol. The median age was 32 years (range 1-64); the median follow-up was 16 months (range 1-94). The subtyping of AML was performed according to the FrenchAmerican-British (FAB) criteria. The stem cell source was allogeneic related bone marrow (n = 53), allogeneic unrelated BM (n = 5), allogeneic unrelated PBSC (n = 2), syngeneic BM (n = 2), autologous BMT unpurged (n = 9), autologous BM purged (n = 9), autologous PBSC (n = 10). Patient characteristics are listed in Table 1 . The conditioning protocol consisted of 16 mg/kg busulfan administered orally in four divided doses daily for 4 days. Cyclophosphamide 30 mg/kg was given intravenously over 1 h for 2 days and etoposide 30 mg/kg (n = 60) or 45 mg/kg (n = 30) was administered intravenously, undiluted over 6 h (see Table 2 ). This was a single center study and all patients were referred to our center for bone marrow transplantation. The protocol was performed as a de-escalating study, starting with 45 mg/kg etoposide in the first 30 patients followed by 30 mg/kg etoposide in the consecutive patients. The primary objective of the present study was to compare toxicity and outcome of different etoposide doses as con- ditioning therapy with fixed doses of busulfan and cyclophosphamide. Phenytoin was given to prevent busulfaninduced seizures until 2 days after stopping busulfan. Uroepithelial prophylaxis was achieved with hyperhydration and mesna. Bone marrow or peripheral blood stem cells were reinfused 24-48 h after the last cyclophosphamide dose. All patients were treated with granulocyte colonystimulating factor, starting on day ϩ1 until engraftment. The transplant protocol was approved by the local ethics committee and all patients gave written informed consent.
GVHD prophylaxis
GVHD prophylaxis in allogeneic transplantation consisted of cyclosporin A (3 mg/kg) starting on day Ϫ1 until day 180. Patients received 10 mg/m 2 methotrexate i.v. on days ϩ1, ϩ3 and ϩ6. Acute GVHD was diagnosed and graded according to the Glucksberg criteria 19 and treated with methylprednisolone. Since 1995, all patients additionally received metronidazole as GVHD prophylaxis. In unrelated transplantation further GVHD prophylaxis was with antithymocyte globulin (90 mg/kg, Fresenius, Gräfeling, Germany) given as part of the conditioning regimen, metronidazole and IgM enriched immunoglobulin as described previously. 20 
Infection prophylaxis
Infection prophylaxis consisted of ciprofloxacin 2 ϫ 500 mg daily or ofloxacin 2 ϫ 200 mg daily, fluconazole 2 ϫ 100 mg daily and amphotorian suspension. Trimethoprim-sulfamethoxazol 2 ϫ 160 mg daily was given 3 days a week until day 360.
Regimen-related toxicities
Regimen-related toxicities affecting the renal, hepatic, cardiac, pulmonary, gastrointestinal, and the CNS system and mucous membranes were graded using the Bearman score 21 and the maximum score for each organ system was recorded. Skin toxicity was described as mild in the event of erythema or as severe in the event of desquamation. Attempts were made to exclude toxicities due to GVHD from this evaluation.
Statistical analysis
Statistic analyses were performed using WinSTAT software (Kalmia Co, USA). Disease-free (DFS) and overall survival (OS) were calculated by the methods of Kaplan and Meier. 22 The log rank test and the Mann-Whitney test were used for comparison. A P value of Ͻ0.05 was considered significant.
Results
Transplant-related toxicity and GVHD
All patients were evaluable for toxicity. The main toxicity of both VP-16 groups was mucositis grade II and hepatotoxicity. Treatment with 45 mg/kg VP-16 resulted in a higher incidence of grade I/II liver toxicity than did 30 mg/kg (67% vs 43%, P = 0.03). The incidence of VOD was also higher in the 45 mg/kg than in the 30 mg/kg group (23% vs 12%, P = 0.04). The treatment-related mortality was 16% in the 30 mg/kg group and 26% in the 45 mg/kg group (P = 0.1) mainly due to infection (fungal, bacterial sepsis, CMV), interstitial pneumonia (see Tables 3 and 5 ). Skin toxicity was mild in both groups (18 and 26%), and resolved completely. None of the patients developed cardiac or CNS toxicity. GVHD grades I/I and III/IV were slightly but not significantly higher in the 45 mg/kg group (30 vs 18% and 13 vs 5%).
Hematopoietic engraftment
The was no difference in leukocyte engraftment between the two VP-16 dose groups. The median days to leukocyte engraftment Ͼ1/nl were 17 days (range 9-39) in the 30 mg/kg group and 16 days (range 12-47) in the 45 mg/kg group. Fifty-seven patients were evaluable for platelet engraftment Ͼ20/nl. In the 45 mg/kg group, platelet engraftment was observed after a median of 21 days (range 13-158) and in the 30 mg/kg group, after a median of 22 days (range 22-365) (Table 4) .
Response, relapse and survival
After a median follow-up of 16 months 11 patients (18%) in the 30 mg/kg group and eight patients (26%) in the 45 mg/kg group relapsed. The overall relapse rate was 20% and occurred mostly after autologous transplantation (40%) or allogeneic transplantation beyond first complete remission (27%). In allogeneic-related transplants in first CR, no relapses occurred after a median follow-up of 3 years in either etoposide group (Tables 6 and 7) . Only one patient developed MDS 4 years post transplantation but chimerism analysis showed Ͼ95% donor cells. The estimated 3 year disease-free survival for all patients was 62% in the 30 mg/kg group and 40% in the 45 mg/kg group (P = 0.03) (Figure 2 ). The 3-year estimated overall survival was 63% in the 30 mg/kg group and 41% in the 45 mg/kg group (P = 0.06) (Figure 1 ). For the group of patients transplanted in first CR from an HLA-identical sibling the estimated 3-year disease-free survival was 80% in the 30 mg/kg group and 66% in the 45 mg/kg group (P = 0.4) (Figure 3 ). 
Discussion
The optimal conditioning regimen for AML is still controversial. The combination of busulfan plus cyclophosphamide (Bu/Cy) has been widely used in patients with hematological malignancies. Initial studies using busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) provided an effective alternative to TBI plus cyclophosphamide in the treatment of AML. 23 Modification of this regimen by lowering the cyclophosphamide dose to 120 mg/kg appears to be equally effective and less toxic. 24 Recently, a followup of a French study comparing busulfan/cyclophosphamide (120 mg/kg) with TBI/cyclophosphamide for allogeneic transplantation in first CR of AML showed a lower relapse rate (28% vs 38%) and a longer disease-free survival (58% vs 48%) for patients treated with TBI/cyclophosphamide. Furthermore, the Bu/Cy regimen resulted in a higher incidence of liver toxicity and GVHD. 25 A retrospective study of the European Cooperative Group for Blood and Marrow Transplantion (EBMT) compared TBI/Cy with Bu/Cy for allogeneic and autologous stem cell transplantation in AML and ALL. Relapse, survival and disease-free survival did not differ between the regimens, but VOD was more common in the Bu/Cy group. 26 A recent meta-analysis compared five randomized trials of Bu/Cy vs TBI-containing regimens in allogeneic stem cell transplantation. Survival and disease-free survival were better in the TBI group but the differences did not reach statistical significance. Again, there was a significantly higher incidence of VOD with the Bu/Cy regimen. 27 However, both arms had a substantial relapse rate, and the purpose of our study was to incorporate the active drug etoposide into the busulfan/ cyclophosphamide regimen in an attempt to reduce the relapse rate. The second aim of our study was to determine the influence of different etoposide doses (30 or 45 mg/kg) on relapse rate and toxicity. The efficacy of high-dose etoposide in advanced hematological malignancies has been confirmed in several studies. [15] [16] [17] In combination with TBI, high-dose etoposide followed by allogeneic stem cell transplantation resulted in a disease-free survival of 43% and a relapse rate of 32% in patients with advanced leukemia. 28, 29 In a comparative study of AML beyond first CR, Bu/Cy showed an advantage without significance in terms of survival, but the TBI/etoposide regimen resulted in less VOD and GVHD. 30 The feasibility of using high-dose busulfan, cyclophosphamide and etoposide in the setting of allogeneic bone marrow transplantation for high risk leukemia has been evaluated and revealed a high treatment-related mortality, mainly due to GVHD, aspergillosis, and failure of Table 7 Relationship between etoposide dose, stem cell source and relapse A study with Bu/Cy/etoposide (40 mg/kg) was conducted by Crilley et al 18 in 84 patients with hematologic malignancies undergoing autologous or allogenic bone marrow transplantation. Mucositis and skin problems were the most frequent extrameduallary toxicity and toxic death because of VOD or pulmonary hemorrhage occuring in 8% of the patients.
The critical issue concerning etoposide use in high-dose chemotherapy regimens is the dose. Several studies observed a dose-response effect of etoposide in terms of extramedullary toxicity, with a maximum tolerated dose of 60-70 mg/kg. [14] [15] [16] 32, 33 Escalating doses of etoposide (30 to 40 mg/kg) were added to busulfan and cyclophosphamide in 11 patients undergoing allogeneic or autologous transplantation. The authors concluded that the regimen could be administered with tolerable toxicity, but expressed concern over skin and hepatic toxicity. 17 Toxicity of the liver and mucositis were the main toxicities in our study. Liver toxicity and veno-occlusive disease were more frequent in the 45 mg/kg group; however, the only fatal case of VOD occurred in the 30 mg/kg group. Treatment-related mortality for all patients was 20% and 23% for allogeneic transplantation in first CR, mainly due to fungal and viral infections, interstitial pneumonia, liver toxicity or GVHD. The incidence of GVHD in allogeneic transplantation was higher in patients treated with 45 mg/kg than with 30 mg/kg, which might relate to the higher organ toxicity. Treatment-related mortality was higher for patients treated with 45 mg/kg etoposide than for patients treated with 30 mg/kg (30 vs 20%). Fatal interstitial pneumonia with pulmonary hemorrhage was observed in four cases (three at 30 mg/kg and one at 45 mg/kg) within 100 days after transplantation, which might be due to high-dose etoposide. 18 However, several other factors including busulfan can cause interstitial pneumonia or pulmonary hemorrhage.
High-dose etoposide in combination with busulfan followed by autologous transplantation has been used in patients with acute non-lymphoblastic leukemia resulting in a disease-free survival of 57% and a relapse rate of only 28%. 5 The relapse rate of all patients in our study who received busulfan, cyclophosphamide and etoposide was only 20%. For patients transplanted from a HLA-identical sibling in first remission no relapses occurred after a median follow-up of 3 years, as published recently by our group. 34 Most relapses occurred after autologous stem cell transplantation, especially in advanced disease (40%). We observed no difference in relapse rate between 30 mg/kg and 45 mg/kg etoposide, suggesting that the lower dose of etoposide might be sufficient to inhibit relapse.
In conclusion, etoposide in doses of 30 or 45 mg/kg in combination with busulfan and cyclophosphamide is a highly active preparative regimen in AML resulting in a low relapse rate and tolerable toxicity, especially for patients in first CR with an HLA-identical sibling who undergo allogeneic stem cell transplantation. The toxicity profile is in favour of 30 mg/kg etoposide. Furthermore, 30 mg/kg etoposide leads to better overall survival than does 45 mg/kg due to reduced mortality with no increase in relapse rate.
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